The results showed that a four-dose regimen provoked immune responses against all 25 assessed serotypes.

Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal ...

Are you up to date on all your shots? Most people aren't, experts say—here are the vaccines you should be asking your doctor ...

Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 ...

But a modified intent-to-treat analysis showed a noninferior vaccine efficacy rate ...

Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination. For pharmacists counseling patients this ...

Pfizer's 25-valent paediatric pneumococcal conjugate vaccine candidate shows robust phase 2 data at IDWeek 2026: New York Tuesday, October 27, 2026, 12:00 Hrs [IST] Pfizer Inc. an ...

Pfizer (PFE) announced detailed results across serotypes from a Phase 2 study for its investigational 25-valent pneumococcal conjugate vaccine candidate, ...

IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting ...

The Adult Vaccines Market Is Projected To Expand At A 9.5% CAGR, Reaching A Value Of $62.74 Billion By 2030.. Adult Vaccines Market Adult Vaccines Market Repor ...

Read oxford covid vaccine latest news on The Economic Times. oxford covid vaccine updates, oxford covid vaccine developments, ...

Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent ...